Growth Hormone (GH) Isoforms Following Acute 22-kDa GH Injection: Is it Useful to Detect GH Abuse?

Abstract

The aim of the study was to investigate the influence of an acute administration of 22-kDa hGH (22-kDa GH) on 22-kDa GH and 20-kDa GH serum levels, biological activity of GH (Nb2-GH) and on 22-kDa/20-kDa GH ratio, in order to verify whether the assessment of the GH isoforms could be a potential tool for diagnosing GH abuse. Twenty-eight children (21 M, 7 F), age 10.4 ± 0.8 y, affected by idiopathic isolated GH deficiency and 10 children (8 M, 2 F), age 9.2 ± 2.3 y affected by constitutional growth delay, were evaluated. After an overnight fast, a basal blood sample was obtained between 8 a.m. and 9 a.m. and a dose of 22-kDa GH was then administered subcutaneously (0.1U/Kg). Blood was drawn after 2, 4 and 6 h, for the evaluation of 22-kDa GH, Nb2-GH and 20-kDa GH serum levels. Similar results were obtained in patients and controls: a significant rise, although of variable amplitude, of 22-kDa GH and Nb2-GH was found (p < 0.001) and the maximum peak was detected after 4 h in the majority of subjects. No acute changes in 20-kDa GH serum levels were observed. The 22-kDa/20-kDa GH ratio increased progressively, due to the rising levels of 22-kDa GH. A positive correlation was seen between 22-kDa GH and Nb2-GH levels at baseline and at 2, 4 and 6 h (p < 0.014, r = 0.99). Since in normal subjects the ratio of endogenous 22-kDa GH and 20-kDa GH is constant, an altered ratio of 22-kDa/20-kDa GH is highly suggestive of GH abuse. The short period of time available for the evaluation however (within 3 h from GH injection), severely limits this investigational tool in athletes.

Key words

GHD patients - GH bioactivity - 20-kDa - 22-kDa - GH isoforms

References

• 1 Baumann G, Winter R J, Shaw M. Circulating molecular variants of growth hormone in childhood.  Pediatr Res. 1987;  22 21-22
• 2 Baumann G. Growth hormone binding proteins and various forms of growth hormone: implication for measurements.  Acta Paediatr Scand (Suppl). 1990;  370 72-80
• 3 Baumann G. Growth hormone heterogeneity: genes, isohormones, variants and binding proteins.  Endocr Rev. 1991;  12 424-449
• 4 Berglund B, Wide L. Erythropoietin concentrations and isoforms in urine of anonymous Olympic athletes during the Nagano Olympic Games.  Scand J Med Sci Sports. 2002;  12 354-357
• 5 Berglund B, Aulin K P, Wide L. Effect of short-term and intermittent normobaric hypoxia on endogenous erythropoietin isoforms.  Scand J Med Sci Sports. 2003;  13 124-127
• 6 Bozzola M, Zecca M, Locatelli F, Radetti G, Pagani S, Autelli M, Tatò L, Chatelain P. Evaluation of growth hormone bioactivity using the Nb₂ cell bioassay in children with growth disorders.  J Endocrinol Invest. 1998;  21 765-770
• 7 Cooke N E, Ray J, Watson M A, Estes P A, Kuo B A, Liebhaber S A. Human growth hormone gene and the highly homologous growth hormone variant gene display different splicing patterns.  J Clin Invest. 1988;  82 270-275
• 8 Cowell C T. Short stature. In: Brook CGD (ed) Clinical Paediatric Endocrinology. 3rd edition. Oxford: Blackwell Science 1994: 136-172
• 9 DeNoto F M, Moore D D, Goodman H M. Human growth hormone DNA sequence and mRNA structure: possible alternative splicing.  Nucleic Acids Res. 1981;  9 3719-3730
• 10 Greulich W W, Pyle S L. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press 1969
• 11 Ishikawa M, Yokoya S, Tachibana K, Hasegawa Y, Yasuda T, Tokuhiro E, Hashimoto Y, Tanaka T. Serum levels of 20-kilodalton human growth hormone (GH) are parallel to those of 22-kilodalton human GH in normal and short children.  J Clin Endocrinol Metab. 1999;  84 98-104
• 12 Lewis U J, Dunn J T, Bonewald L F, Seavey B K, Vanderlaan W P. A naturally occurring structural variant of human growth hormone.  J Biol Chem. 1978;  253 2679-2687
• 13 Lewis U J, Bonewald L F, Lewis L J. The 20,000-dalton variant of human growth hormone: location of the amino acid deletions.  Biochem Biophys Res Commun. 1980;  92 512-516
• 14 Momomura S, Hashimoto Y, Shimazaki Y, Irie M. Detection of exogenous growth hormone (GH) administration by monitoring ratio of 20-kDaDa- and 22-kDaDa-GH in serum and urine.  Endocr J. 2000;  47 97-101
• 15 Radetti G, Bozzola M, Pagani S, Avanzini M A, Messner H, Belloni C, Hayakawa M. Circulating growth hormone (GH) isoforms and GH bioactivity in preterm neonates.  Pediatr Res. 2000;  48 244-247
• 16 Rolland-Cachera M F, Cole T J, Sempé M, Tichet J, Rossignol C, Charraud A. Body mass index variations: centile from birth to 87 years.  Eur J Clin Nutr. 1991;  45 13-21
• 17 Tanaka T, Shiu R PC, Gout P J, Beer C T, Noble R L, Friesen H G. A new sensitive and specific bioassay for lactogenic hormones: measurements of prolactin and growth hormone in human serum.  J Clin Endocrinol Metab. 1980;  51 1058-1063
• 18 Tanner J M, Whitehouse R H, Takaishi M. Standards from birth to maturity for height, weight, height velocity and weight velocity: British children.  Arch Dis Child. 1966;  41 613-635
• 19 Tanner J M. Foetus into man: physical growth from conception to maturity. Second Edition, Castelmead Publications, Ware 1989
• 20 Walker A, Croze F, Friesen H G. A serum-free medium for culturing lactogen dependent and autonomous Nb2 node lymphoma cells.  Endocrinology. 1987;  120 2389-2397
• 21 Wallace J D, Cuneo R C. Growth hormone abuse in Athletes. A review.  The Endocrinologist. 2000;  10 175-184
• 22 Wallace J D, Cuneo R C, Bidlingmaier M, Lundberg P A, Carlsson L, Boguszewski C L, Hay J, Boroujerdi M, Cittadini A, Dall R, Rosén T, Strasburger C J. Changes in non-22-Kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males.  J Clin Endocrinol Metab. 2001;  86 1731-1737